PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20229187-9 2010 Proteinuria was completely ameliorated in the presence of chronic ACE inhibition in the lisinopril-treated rats compared with the vehicle-treated PCK rats. Lisinopril 88-98 angiotensin I converting enzyme Rattus norvegicus 66-69 18496513-2 2008 Here we examined the effect of chronic renal dysfunction induced by uninephrectomy on fat redistribution and lipid peroxidation in rats treated with an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) for up to 10 months. Lisinopril 199-209 angiotensin I converting enzyme Rattus norvegicus 152-181 19462500-1 2009 OBJECTIVES: To investigate whether the combination of exercise training with the angiotensin-converting enzyme inhibitor lisinopril will have an additional beneficial effect on left ventricular function in spontaneously hypertensive rats. Lisinopril 121-131 angiotensin I converting enzyme Rattus norvegicus 81-110 19164508-3 2009 MWF rats with advanced nephropathy were studied at both 40 weeks and after 20 weeks of observation either with or without treatment with the ACE inhibitor lisinopril. Lisinopril 155-165 angiotensin I converting enzyme Rattus norvegicus 141-144 18496513-2 2008 Here we examined the effect of chronic renal dysfunction induced by uninephrectomy on fat redistribution and lipid peroxidation in rats treated with an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) for up to 10 months. Lisinopril 199-209 angiotensin I converting enzyme Rattus norvegicus 183-186 16574603-1 2006 The role of ACE inhibitors (Lisinopril) in reproductive function remains controversial. Lisinopril 28-38 angiotensin I converting enzyme Rattus norvegicus 12-15 18084312-5 2008 In the presence of lisinopril (ACE inhibitor), but not candoxatril (NEP inhibitor) or apstatin (APP inhibitor), bradykinin also elicited hypotension. Lisinopril 19-29 angiotensin I converting enzyme Rattus norvegicus 31-34 18496146-5 2008 Central infusion of lisinopril caused 70% inhibition of brain ACE and minimal (6%) inhibition in the kidneys. Lisinopril 20-30 angiotensin I converting enzyme Rattus norvegicus 62-65 18192334-6 2008 Lisinopril significantly reduced renal ACE activity without affecting renal ACE2 activity. Lisinopril 0-10 angiotensin I converting enzyme Rattus norvegicus 39-42 18192334-9 2008 Plasma Ang(1-7) and Ang II balance is positively shifted towards the beneficial vasopeptide Ang(1-7) by the ACE inhibitor lisinopril, especially during a low sodium intake. Lisinopril 122-132 angiotensin I converting enzyme Rattus norvegicus 108-111 17889307-5 2007 Selected animals were also treated with the angiotensin-converting enzyme (ACE) inhibitor lisinopril (3 mg/l in diet) for 6 weeks. Lisinopril 90-100 angiotensin I converting enzyme Rattus norvegicus 75-78 16766648-3 2006 The control of blood pressure elicited by 12-day administration of either lisinopril (mean difference change = 92 +/- 2, P < 0.05) or losartan (mean difference change = 69 +/- 2, P < 0.05) was associated with 54% and 33% increases in cardiac ACE2 mRNA and 54% and 43% increases in cardiac ACE mRNA, respectively. Lisinopril 74-84 angiotensin I converting enzyme Rattus norvegicus 242-245 15869762-7 2005 While no treatment was given to rats in group 1, Lisinopril (an ACE inhibitor) was given to rats in group 2 and group 3 for post-operative 7 days in drinking water at 50 and 5 mg/l concentrations, respectively. Lisinopril 49-59 angiotensin I converting enzyme Rattus norvegicus 64-67 16284359-4 2006 Therefore, the current study investigated the ability of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, to modulate oxidative stress in the lung after chronic EtOH ingestion in a well-established rat model. Lisinopril 57-67 angiotensin I converting enzyme Rattus norvegicus 72-101 16284359-4 2006 Therefore, the current study investigated the ability of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, to modulate oxidative stress in the lung after chronic EtOH ingestion in a well-established rat model. Lisinopril 57-67 angiotensin I converting enzyme Rattus norvegicus 103-106 16221218-1 2005 BACKGROUND: Angiotensin-converting enzyme (ACE)2, a homologue of ACE, which is insensitive to ACE inhibitors and forms angiotensin-(1-7) [Ang-(1-7)] from angiotensin II (Ang II) with high efficiency was investigated in response to chronic blockade with lisinopril, losartan, and both drugs combined. Lisinopril 253-263 angiotensin I converting enzyme Rattus norvegicus 12-41 16221218-1 2005 BACKGROUND: Angiotensin-converting enzyme (ACE)2, a homologue of ACE, which is insensitive to ACE inhibitors and forms angiotensin-(1-7) [Ang-(1-7)] from angiotensin II (Ang II) with high efficiency was investigated in response to chronic blockade with lisinopril, losartan, and both drugs combined. Lisinopril 253-263 angiotensin I converting enzyme Rattus norvegicus 43-46 16221218-1 2005 BACKGROUND: Angiotensin-converting enzyme (ACE)2, a homologue of ACE, which is insensitive to ACE inhibitors and forms angiotensin-(1-7) [Ang-(1-7)] from angiotensin II (Ang II) with high efficiency was investigated in response to chronic blockade with lisinopril, losartan, and both drugs combined. Lisinopril 253-263 angiotensin I converting enzyme Rattus norvegicus 65-68 15499219-9 2004 CONCLUSION: MMF and the ACE inhibitor lisinopril attenuated the progression of the fibrogenic process of UUO in an equivalent manner. Lisinopril 38-48 angiotensin I converting enzyme Rattus norvegicus 24-27 15836856-9 2005 Although no treatment was given to rats in group 1, lisinopril (an ACE inhibitor) was given to rats in group 2 for postoperative 7 days in drinking water. Lisinopril 52-62 angiotensin I converting enzyme Rattus norvegicus 67-70 15908024-1 2005 The present study was aimed to investigate the effect of ACE inhibition on trinitrobenzene sulphonic acid (TNBS)-induced colonic inflammation in rats by using captopril and lisinopril. Lisinopril 173-183 angiotensin I converting enzyme Rattus norvegicus 57-60 14769834-4 2004 In NEP-inhibited rats, extravasation produced by the ACE inhibitors captopril and lisinopril was markedly enhanced. Lisinopril 82-92 angiotensin I converting enzyme Rattus norvegicus 53-56 15106813-6 2004 RESULTS: Lisinopril dose-dependently reduced ACE activity in control and TGF-beta1-treated cardiac fibroblasts. Lisinopril 9-19 angiotensin I converting enzyme Rattus norvegicus 45-48 12636872-7 2003 During treatment with the ACE inhibitor lisinopril, proteinuria was lowered by 79+/-9% (mean+/-S.E.M.). Lisinopril 40-50 angiotensin I converting enzyme Rattus norvegicus 26-29 14614522-10 2003 However, an interaction between the ACE inhibitor and spironolactone potentiating the effects of either drug alone was observed with a lower dose of spironolactone (lisinopril and 8 mg.kg-1.day-1 spironolactone). Lisinopril 165-175 angiotensin I converting enzyme Rattus norvegicus 36-39 12586636-8 2003 The ANG-converting enyzme (ACE) inhibitor lisinopril inhibited the maximal response to ANG I in AA and muscular EA by 75 +/- 9% (n = 13) and 70 +/- 7% (n = 13), respectively, but had no effect in thin EA (n = 14). Lisinopril 42-52 angiotensin I converting enzyme Rattus norvegicus 4-25 12586636-8 2003 The ANG-converting enyzme (ACE) inhibitor lisinopril inhibited the maximal response to ANG I in AA and muscular EA by 75 +/- 9% (n = 13) and 70 +/- 7% (n = 13), respectively, but had no effect in thin EA (n = 14). Lisinopril 42-52 angiotensin I converting enzyme Rattus norvegicus 27-30 12676181-4 2003 However, AT(1) receptor binding was significantly higher in the prostate of the TG rat treated with the ACE inhibitor lisinopril compared to the untreated TG rat and comparable to the control SD rat. Lisinopril 118-128 angiotensin I converting enzyme Rattus norvegicus 104-107 12435880-0 2002 Protein kinase C beta isoenzymes in diabetic kidneys and their relation to nephroprotective actions of the ACE inhibitor lisinopril. Lisinopril 121-131 angiotensin I converting enzyme Rattus norvegicus 107-110 12671898-2 2003 We assessed the effects of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, on spontaneously occurring chronic pancreatitis. Lisinopril 27-37 angiotensin I converting enzyme Rattus norvegicus 42-71 12671898-2 2003 We assessed the effects of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, on spontaneously occurring chronic pancreatitis. Lisinopril 27-37 angiotensin I converting enzyme Rattus norvegicus 73-76 12671898-6 2003 Lisinopril significantly reduced serum ACE activity but it did not affect pancreatic activity. Lisinopril 0-10 angiotensin I converting enzyme Rattus norvegicus 39-42 12435880-2 2002 We investigated the influence of streptozotocin (STZ)-induced diabetes mellitus and of treatment with the ACE inhibitor lisinopril (4 mg/kg p.o. Lisinopril 120-130 angiotensin I converting enzyme Rattus norvegicus 106-109 12435880-7 2002 The data suggest that the nephroprotective actions of the ACE inhibitor lisinopril in experimental diabetes mellitus were associated with and thus could be mediated in part by inhibition of diabetes-induced activation of PKC beta isoenzymes in the renal cortex. Lisinopril 72-82 angiotensin I converting enzyme Rattus norvegicus 58-61 11358940-1 2001 We have previously demonstrated that antihypertensive treatment with doxazosin (DZN), an alpha-adrenergic blocker, and lisinopril (LIS), an ACE inhibitor, reverse glomerular sclerosis in corpulent spontaneously hypertensive rats with type 2 diabetes. Lisinopril 119-129 angiotensin I converting enzyme Rattus norvegicus 140-143 11358940-1 2001 We have previously demonstrated that antihypertensive treatment with doxazosin (DZN), an alpha-adrenergic blocker, and lisinopril (LIS), an ACE inhibitor, reverse glomerular sclerosis in corpulent spontaneously hypertensive rats with type 2 diabetes. Lisinopril 131-134 angiotensin I converting enzyme Rattus norvegicus 140-143 11116132-4 2000 The ACE inhibitor lisinopril and the angiotensin type 1 receptor antagonist losartan both increased retinal renin levels and prevented inner retinal blood vessel growth. Lisinopril 18-28 angiotensin I converting enzyme Rattus norvegicus 4-7 11151038-0 2001 Angiotensin-converting enzyme inhibition by lisinopril enhances liver regeneration in rats. Lisinopril 44-54 angiotensin I converting enzyme Rattus norvegicus 0-29 11151038-4 2001 We have investigated the effect of ACE inhibition by lisinopril on liver regeneration after partial hepatectomy. Lisinopril 53-63 angiotensin I converting enzyme Rattus norvegicus 35-38 11151038-10 2001 Plasma ACE activity measured by radioenzymatic assay was significantly higher in the saline group than in the lisinopril-treated group (P<0.001), with 81% ACE inhibition. Lisinopril 110-120 angiotensin I converting enzyme Rattus norvegicus 7-10 11151038-10 2001 Plasma ACE activity measured by radioenzymatic assay was significantly higher in the saline group than in the lisinopril-treated group (P<0.001), with 81% ACE inhibition. Lisinopril 110-120 angiotensin I converting enzyme Rattus norvegicus 158-161 11331849-8 2001 All three ACE inhibitors prevented AAA development (mean DeltaAD: CP, 67% +/- 4%; LP, 18% +/- 12%; and EP, 14% +/- 3%; each P <.05 vs controls). Lisinopril 82-84 angiotensin I converting enzyme Rattus norvegicus 10-13 11096048-8 2000 In a group of PHN rats with advanced disease and severe proteinuria, a dose of lisinopril high enough to inhibit renal ACE activity failed to reduce proteinuria and also did not limit NF-kB activation, which was sustained over time, along with MCP-1 gene overexpression and interstitial inflammation. Lisinopril 79-89 angiotensin I converting enzyme Rattus norvegicus 119-122 11967821-11 2000 RESULTS: Fibroblasts contained two types of activity of hip-his-leu degradation, namely a lisinopril-dependent activity (ACE activity) and a lisinopril-independent activity ("ACE-like" activity) which is performed by peptidase(s) other than ACE. Lisinopril 90-100 angiotensin I converting enzyme Rattus norvegicus 121-124 11004022-5 2000 Under dehydrated conditions, the enhanced endotoxin-induced fever was significantly inhibited by the angiotensin-converting enzyme inhibitor lisinopril, but the IL-1beta fever was not. Lisinopril 141-151 angiotensin I converting enzyme Rattus norvegicus 101-130 11053044-4 2000 The ANG-converting enzyme (ACE) inhibitor lisinopril abolished the generation of ANG-(1---5), as well as that of smaller metabolites. Lisinopril 42-52 angiotensin I converting enzyme Rattus norvegicus 4-25 11053044-4 2000 The ANG-converting enzyme (ACE) inhibitor lisinopril abolished the generation of ANG-(1---5), as well as that of smaller metabolites. Lisinopril 42-52 angiotensin I converting enzyme Rattus norvegicus 27-30 10993857-2 2000 In spontaneously hypertensive rats, myocardial fibrosis was regressed and LV diastolic function was improved by treatment with the angiotensin-converting enzyme inhibitor lisinopril. Lisinopril 171-181 angiotensin I converting enzyme Rattus norvegicus 131-160 10893698-0 2000 Role of angiotensin-converting enzyme inhibitor, lisinopril, on spermatozoal functions in rats. Lisinopril 49-59 angiotensin I converting enzyme Rattus norvegicus 8-37 10983838-2 2000 SHR were fed alcohol for six weeks while taking the angiotensin converting enzyme (ACE) inhibitor lisinopril. Lisinopril 98-108 angiotensin I converting enzyme Rattus norvegicus 83-86 10949912-14 2000 Furthermore, the chronic inhibition of serum and exudate ACE levels by lisinopril treatment did not affect the exudate volume in F344/N rats, indicating that several factors besides ACE were involved in the control of carrageenan-induced exudation. Lisinopril 71-81 angiotensin I converting enzyme Rattus norvegicus 57-60 10949912-8 2000 ACE kinetic and inhibition studies were performed using specific substrates (Hip-His-Leu and Acetyl-Seryl-Aspartyl-Acetyl-Lysyl-Proline) and inhibitors (lisinopril, captopril and quinaprilat) for each C- and N-terminal active site. Lisinopril 153-163 angiotensin I converting enzyme Rattus norvegicus 0-3 11501132-9 1999 After treatment with ACE inhibitor-Lisinopril, the ACE activities, AII levels and calcium contents were significantly decreased compared to the burn group. Lisinopril 35-45 angiotensin I converting enzyme Rattus norvegicus 21-24 11450501-0 2000 The influence of the ACE inhibitor lisinopril on the glomerular metabolism of proteolytic enzymes in diabetic rats. Lisinopril 35-45 angiotensin I converting enzyme Rattus norvegicus 21-24 10516341-4 1999 Animals treated with the ACE inhibitor lisinopril from 20 weeks of age (time when proteinuria is already important) and age-matched untreated rats were followed for 10 weeks. Lisinopril 39-49 angiotensin I converting enzyme Rattus norvegicus 25-28 10642323-5 2000 The addition of the ACE inhibitor lisinopril to the perfusion buffer augmented levels of Ang-(1-7) in periods 3 (144+/-39 fmol) and 4 (163+/-35 fmol; P<0.05 versus 1 or 2, n=8). Lisinopril 34-44 angiotensin I converting enzyme Rattus norvegicus 20-23 11501132-9 1999 After treatment with ACE inhibitor-Lisinopril, the ACE activities, AII levels and calcium contents were significantly decreased compared to the burn group. Lisinopril 35-45 angiotensin I converting enzyme Rattus norvegicus 51-54 10188971-3 1999 With daily oral administration of lisinopril (5 mg kg(-1), twice a day), which is an inhibitor of angiotensin converting enzyme, a major kininase in plasma, the development of hypertension was not suppressed. Lisinopril 34-44 angiotensin I converting enzyme Rattus norvegicus 98-127 9886768-9 1998 The angiotensin converting enzyme (ACE) inhibitor lisinopril blunted the reflex responses to PBG in anaesthetized as well as conscious animals. Lisinopril 50-60 angiotensin I converting enzyme Rattus norvegicus 4-33 9886768-9 1998 The angiotensin converting enzyme (ACE) inhibitor lisinopril blunted the reflex responses to PBG in anaesthetized as well as conscious animals. Lisinopril 50-60 angiotensin I converting enzyme Rattus norvegicus 35-38 9831227-8 1998 The power of the high-frequency spectral component increased in all animal preparations under treatment with prazosin, dl-propranolol, endothelin-1 and the angiotensin converting enzyme (ACE) inhibitors captopril, lisinopril, quinapril and ramipril. Lisinopril 214-224 angiotensin I converting enzyme Rattus norvegicus 187-190 9710808-7 1998 Pharmacologic intervention studies with lisinopril or losartan indicate Ang II plays a role in the reciprocal regulation of ACE mRNA expression, which modulates Ang II levels at sites of repair. Lisinopril 40-50 angiotensin I converting enzyme Rattus norvegicus 124-127 7794953-3 1995 The kinetic transport parameters of three ACE-inhibitors, enalapril, enalaprilat, and lisinopril, have been determined in an in vivo system using rat intestine. Lisinopril 86-96 angiotensin I converting enzyme Rattus norvegicus 42-45 9293971-5 1997 Additional groups of MI rats were treated with the ACE inhibitor lisinopril, alone or in combination with icatibant. Lisinopril 65-75 angiotensin I converting enzyme Rattus norvegicus 51-54 9262354-23 1997 PGE2 (100 ng), of the angiotensin-converting enzyme (ACE) inhibitor lisinopril (5 and 10 microg) attenuated the PGE2-induced fever. Lisinopril 68-78 angiotensin I converting enzyme Rattus norvegicus 22-51 9262354-23 1997 PGE2 (100 ng), of the angiotensin-converting enzyme (ACE) inhibitor lisinopril (5 and 10 microg) attenuated the PGE2-induced fever. Lisinopril 68-78 angiotensin I converting enzyme Rattus norvegicus 53-56 8938667-12 1996 The oedema induced by collagenase was also increased by lisinopril, another ACE inhibitor, administered locally in combination with apstatin, an inhibitor of aminopeptidase P (AmP). Lisinopril 56-66 angiotensin I converting enzyme Rattus norvegicus 76-79 8707393-4 1996 It has been shown in 14-week-old SHR with early hypertensive heart disease that myocardial fibrosis could be reversed and myocardial diastolic stiffness normalized by 12-week treatment with the angiotensin-converting enzyme inhibitor lisinopril. Lisinopril 234-244 angiotensin I converting enzyme Rattus norvegicus 194-223 8707393-8 1996 Thus, long-term angiotensin-converting enzyme inhibition with lisinopril normalized arterial pressure and LVH, reversed myocardial fibrosis, and improved abnormal myocardial diastolic stiffness in advanced hypertensive heart disease in SHR. Lisinopril 62-72 angiotensin I converting enzyme Rattus norvegicus 16-45 9568846-8 1998 Maximum TGF responses were 8.9 +/- 1.0 and 17.5 +/- 1.5 mmHg in 11- and 26-week-old rats that had been treated with the ACE-i lisinopril in the drinking water started when the animals were 7 weeks of age. Lisinopril 126-136 angiotensin I converting enzyme Rattus norvegicus 120-123 9218184-6 1997 ACE inhibitor treatment with 10 mg/kg body weight lisinopril daily for 14 days by gavage reduced neointima proliferation in hypertensive and normotensive rats (neointima: media ratio: 0.35 +/- 0.02 for SHR, P < 0.01, versus untreated SHR with balloon injury; 0.28 +/- 0.01 for SD, P < 0.01, versus untreated SD rats with balloon injury). Lisinopril 50-60 angiotensin I converting enzyme Rattus norvegicus 0-3 8699329-1 1996 Peptidic drugs such as beta-lactam aminocephalosporin antibiotics (e.g., cephalexin) and the ACE inhibitors lisinopril, quinapril, and benzazepril are apparently absorbed, at least in part, by the intestinal dipeptide transporter system (DTS). Lisinopril 108-118 angiotensin I converting enzyme Rattus norvegicus 93-96 7586374-6 1995 Administration of lisinopril attenuated the development of left and right ventricular hypertrophy in this model and was accompanied by an attenuation of the upregulation of the ACE, collagen type I-alpha, and vimentin mRNAs. Lisinopril 18-28 angiotensin I converting enzyme Rattus norvegicus 177-180 7586374-7 1995 Because the activity of the circulating RAS in the aortocaval shunt rats was not higher than that in the sham-operated rats, the effects of lisinopril in attenuating the ventricular hypertrophy may be due to inhibition of the increased ACE in the ventricle. Lisinopril 140-150 angiotensin I converting enzyme Rattus norvegicus 236-239 7602241-4 1995 We sought to determine whether the ACE inhibitor lisinopril would attenuate fibrous tissue ACE binding and fibrous tissue formation in the myocardium of rats receiving AngII. Lisinopril 49-59 angiotensin I converting enzyme Rattus norvegicus 35-38 7602241-4 1995 We sought to determine whether the ACE inhibitor lisinopril would attenuate fibrous tissue ACE binding and fibrous tissue formation in the myocardium of rats receiving AngII. Lisinopril 49-59 angiotensin I converting enzyme Rattus norvegicus 91-94 7602241-6 1995 Cardiac ACE binding density was localized and quantified by in vitro autoradiography with [125I]-labeled 351A, a tyrosyl derivative of lisinopril, while fibrosis was identified by light microscopy in serial sections stained with picrosirius red. Lisinopril 135-145 angiotensin I converting enzyme Rattus norvegicus 8-11 7637261-6 1995 Nephrectomized animals were left untreated or treated with the ACE inhibitor lisinopril in drinking water. Lisinopril 77-87 angiotensin I converting enzyme Rattus norvegicus 63-66 7528985-1 1994 To clarify whether angiotensin converting enzyme (ACE) inhibitors prevent progressive renal injury directly by their antihypertensive effect we administered the ACE inhibitor lisinopril to male MWF/Ztm rats as a single daily dose that lowered blood pressure for only 9 of 24 h. We investigated the effects of this treatment in short- and long-term studies and compared them with another antihypertensive drug, the calcium channel blocker nitrendipine, given to partially control blood pressure as done with the ACE inhibitor. Lisinopril 175-185 angiotensin I converting enzyme Rattus norvegicus 161-164 7528985-1 1994 To clarify whether angiotensin converting enzyme (ACE) inhibitors prevent progressive renal injury directly by their antihypertensive effect we administered the ACE inhibitor lisinopril to male MWF/Ztm rats as a single daily dose that lowered blood pressure for only 9 of 24 h. We investigated the effects of this treatment in short- and long-term studies and compared them with another antihypertensive drug, the calcium channel blocker nitrendipine, given to partially control blood pressure as done with the ACE inhibitor. Lisinopril 175-185 angiotensin I converting enzyme Rattus norvegicus 161-164 7528840-1 1994 To assess the role of angiotensin II (AII) in development of myocardial injury during ischemia and reperfusion, the effects of short-term treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril were compared with the effects of short-term treatment with L-158,338, an AII antagonist, in isolated working rat heart. Lisinopril 203-213 angiotensin I converting enzyme Rattus norvegicus 188-191 7955203-11 1994 Sustained inhibition of renal ACE during long-term therapy may contribute to the beneficial effect of high-dose lisinopril. Lisinopril 112-122 angiotensin I converting enzyme Rattus norvegicus 30-33 7955203-12 1994 Low-dose lisinopril, although exerting sustained inhibition of the plasma ACE, does not improve survival after myocardial infarction. Lisinopril 9-19 angiotensin I converting enzyme Rattus norvegicus 74-77 8298535-2 1993 The effect of lisinopril, a potent inhibitor of angiotensin converting enzyme (ACE), injected into the medial preoptic area (MPOA) on water intake was investigated in male Holtzman rats (200-250 g). Lisinopril 14-24 angiotensin I converting enzyme Rattus norvegicus 48-77 8174603-4 1994 Reduction in affinity at the amino binding site of somatic angiotensin converting enzyme was related to an increased side chain size (lung KDA (pM): Ro 31-8472 175 +/- 38, lisinopril 2205 +/- 1832, and 351A 2271 +/- 489), or hydrophobicity of the competing unlabelled angiotensin converting enzyme inhibitor (lung KDA (pM): quinaprilat 1267 +/- 629 and perindoprilat 824 +/- 6). Lisinopril 172-182 angiotensin I converting enzyme Rattus norvegicus 59-88 8298535-2 1993 The effect of lisinopril, a potent inhibitor of angiotensin converting enzyme (ACE), injected into the medial preoptic area (MPOA) on water intake was investigated in male Holtzman rats (200-250 g). Lisinopril 14-24 angiotensin I converting enzyme Rattus norvegicus 79-82 1846675-8 1991 The inhibition of AI stimulation of aldosterone release by lisinopril is mostly due to lisinopril inhibition of ACE and resulting decreased conversion of AI to AII. Lisinopril 59-69 angiotensin I converting enzyme Rattus norvegicus 112-115 8284265-7 1993 In both WKY and SHR, lisinopril had a greater effect in inhibiting plasma and cerebrospinal fluid ACE, reducing levels of plasma angiotensinogen, and increasing the concentrations of authentic Ang II. Lisinopril 21-31 angiotensin I converting enzyme Rattus norvegicus 98-101 8097091-3 1993 Chronic treatment with ACE inhibitors (captopril or lisinopril) for 25 days, followed by 1 day without treatment, increased plasma ACE, but only slightly modified lung, aorta, heart and kidney specific ACE activity. Lisinopril 52-62 angiotensin I converting enzyme Rattus norvegicus 23-26 8097091-3 1993 Chronic treatment with ACE inhibitors (captopril or lisinopril) for 25 days, followed by 1 day without treatment, increased plasma ACE, but only slightly modified lung, aorta, heart and kidney specific ACE activity. Lisinopril 52-62 angiotensin I converting enzyme Rattus norvegicus 131-134 8097091-3 1993 Chronic treatment with ACE inhibitors (captopril or lisinopril) for 25 days, followed by 1 day without treatment, increased plasma ACE, but only slightly modified lung, aorta, heart and kidney specific ACE activity. Lisinopril 52-62 angiotensin I converting enzyme Rattus norvegicus 131-134 8392403-0 1993 Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Lisinopril 130-140 angiotensin I converting enzyme Rattus norvegicus 90-119 8392403-1 1993 The effect of treatment of rats with the angiotensin converting enzyme inhibitor lisinopril after 5 weeks of untreated streptozotocin-diabetes was examined by daily monitoring of sciatic motor conduction velocity to tibialis anterior muscle. Lisinopril 81-91 angiotensin I converting enzyme Rattus norvegicus 41-70 1325885-6 1992 There was marked variation in ACE inhibitor binding affinity at the two binding sites of lung ACE across the panel of ACE inhibitors studied (equilibrium dissociation constant; Kd; pmol/L) for site one vs site two: cilazaprilat 40 +/- 3 vs 430 +/- 92*; lisinopril 25 +/- 1 vs 848 +/- 107**; and quinaprilat 4 +/- 1 vs 1869 +/- 720; *P less than 0.05; **P less than 0.005, t-test, n = 3). Lisinopril 253-263 angiotensin I converting enzyme Rattus norvegicus 30-33 1325885-6 1992 There was marked variation in ACE inhibitor binding affinity at the two binding sites of lung ACE across the panel of ACE inhibitors studied (equilibrium dissociation constant; Kd; pmol/L) for site one vs site two: cilazaprilat 40 +/- 3 vs 430 +/- 92*; lisinopril 25 +/- 1 vs 848 +/- 107**; and quinaprilat 4 +/- 1 vs 1869 +/- 720; *P less than 0.05; **P less than 0.005, t-test, n = 3). Lisinopril 253-263 angiotensin I converting enzyme Rattus norvegicus 94-97 1325885-6 1992 There was marked variation in ACE inhibitor binding affinity at the two binding sites of lung ACE across the panel of ACE inhibitors studied (equilibrium dissociation constant; Kd; pmol/L) for site one vs site two: cilazaprilat 40 +/- 3 vs 430 +/- 92*; lisinopril 25 +/- 1 vs 848 +/- 107**; and quinaprilat 4 +/- 1 vs 1869 +/- 720; *P less than 0.05; **P less than 0.005, t-test, n = 3). Lisinopril 253-263 angiotensin I converting enzyme Rattus norvegicus 94-97 1724523-0 1991 Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. Lisinopril 136-146 angiotensin I converting enzyme Rattus norvegicus 0-29 1724523-2 1991 ACE activity in all regions of the heart, kidney, and serum was markedly reduced 4 h after administration of lisinopril and zofenopril and only partially recovered toward control levels at 24 h. After captopril treatment, ACE activity was partially inhibited in heart, kidney, and serum at 1 h and fully recovered toward control levels in most regions at 24 h. These results suggest that these inhibitors reduce ACE in all regions of the heart and kidney without regional selective inhibition. Lisinopril 109-119 angiotensin I converting enzyme Rattus norvegicus 0-3 1724523-2 1991 ACE activity in all regions of the heart, kidney, and serum was markedly reduced 4 h after administration of lisinopril and zofenopril and only partially recovered toward control levels at 24 h. After captopril treatment, ACE activity was partially inhibited in heart, kidney, and serum at 1 h and fully recovered toward control levels in most regions at 24 h. These results suggest that these inhibitors reduce ACE in all regions of the heart and kidney without regional selective inhibition. Lisinopril 109-119 angiotensin I converting enzyme Rattus norvegicus 222-225 1724523-2 1991 ACE activity in all regions of the heart, kidney, and serum was markedly reduced 4 h after administration of lisinopril and zofenopril and only partially recovered toward control levels at 24 h. After captopril treatment, ACE activity was partially inhibited in heart, kidney, and serum at 1 h and fully recovered toward control levels in most regions at 24 h. These results suggest that these inhibitors reduce ACE in all regions of the heart and kidney without regional selective inhibition. Lisinopril 109-119 angiotensin I converting enzyme Rattus norvegicus 222-225 1724523-3 1991 Lisinopril and zofenopril at these doses produced longer-lasting ACE inhibition than captopril. Lisinopril 0-10 angiotensin I converting enzyme Rattus norvegicus 65-68 8384939-4 1993 With the ACE inhibitor 125I-351A, a derivative of lisinopril, as a radioligand on coronal sections of LVH and control hearts, in vitro autoradiography demonstrated ACE binding in aorta, coronary arteries, atria, and ventricles of both groups. Lisinopril 50-60 angiotensin I converting enzyme Rattus norvegicus 9-12 8384939-4 1993 With the ACE inhibitor 125I-351A, a derivative of lisinopril, as a radioligand on coronal sections of LVH and control hearts, in vitro autoradiography demonstrated ACE binding in aorta, coronary arteries, atria, and ventricles of both groups. Lisinopril 50-60 angiotensin I converting enzyme Rattus norvegicus 164-167 1325031-4 1992 Analysis of displacement of 125I-Ro 31-8472 binding from ACE by ACE inhibitors 351A and lisinopril yielded biphasic curves for pulmonary, renal, and plasma ACE and a monophasic curve for ACE from the testis. Lisinopril 88-98 angiotensin I converting enzyme Rattus norvegicus 57-60 1325031-4 1992 Analysis of displacement of 125I-Ro 31-8472 binding from ACE by ACE inhibitors 351A and lisinopril yielded biphasic curves for pulmonary, renal, and plasma ACE and a monophasic curve for ACE from the testis. Lisinopril 88-98 angiotensin I converting enzyme Rattus norvegicus 64-67 1325031-4 1992 Analysis of displacement of 125I-Ro 31-8472 binding from ACE by ACE inhibitors 351A and lisinopril yielded biphasic curves for pulmonary, renal, and plasma ACE and a monophasic curve for ACE from the testis. Lisinopril 88-98 angiotensin I converting enzyme Rattus norvegicus 64-67 1325031-4 1992 Analysis of displacement of 125I-Ro 31-8472 binding from ACE by ACE inhibitors 351A and lisinopril yielded biphasic curves for pulmonary, renal, and plasma ACE and a monophasic curve for ACE from the testis. Lisinopril 88-98 angiotensin I converting enzyme Rattus norvegicus 64-67 1333254-2 1992 In the ex vivo- and in vitro-experiments using isolated rat aorta, vascular prostacyclin (PGI2) production is dose-dependently stimulated by the ACE inhibitors captopril, lisinopril, and ramipril. Lisinopril 171-181 angiotensin I converting enzyme Rattus norvegicus 145-148 1653792-0 1991 Measurement of angiotensin converting enzyme induction and inhibition using quantitative in vitro autoradiography: tissue selective induction after chronic lisinopril treatment. Lisinopril 156-166 angiotensin I converting enzyme Rattus norvegicus 15-44 1653792-11 1991 Despite this, during chronic treatment with lisinopril, ACE activity in all of these organs was inhibited with low levels of free ACE. Lisinopril 44-54 angiotensin I converting enzyme Rattus norvegicus 56-59 1653792-11 1991 Despite this, during chronic treatment with lisinopril, ACE activity in all of these organs was inhibited with low levels of free ACE. Lisinopril 44-54 angiotensin I converting enzyme Rattus norvegicus 130-133 1846675-8 1991 The inhibition of AI stimulation of aldosterone release by lisinopril is mostly due to lisinopril inhibition of ACE and resulting decreased conversion of AI to AII. Lisinopril 87-97 angiotensin I converting enzyme Rattus norvegicus 112-115 34339022-2 2021 Coenzyme Q10 (Q10) as a powerful antioxidant and lisinopril (LIS) as an angiotensin-converting enzyme inhibitor seem to provide protection against DOX-induced cardiotoxicity. Lisinopril 49-59 angiotensin I converting enzyme Rattus norvegicus 72-101 2167741-10 1990 The rank order of potency of the ACE inhibitors was quinaprilat = benazeprilat greater than perindoprilat greater than 351A greater than lisinopril greater than fosinoprilat. Lisinopril 137-147 angiotensin I converting enzyme Rattus norvegicus 33-36 2158900-4 1990 The captopril- and lisinopril-induced stimulation of vascular 6-keto-PGF1 alpha production was also significantly decreased when the BK antagonist was added to the incubation medium together with the ACE inhibitors. Lisinopril 19-29 angiotensin I converting enzyme Rattus norvegicus 200-203 34339022-2 2021 Coenzyme Q10 (Q10) as a powerful antioxidant and lisinopril (LIS) as an angiotensin-converting enzyme inhibitor seem to provide protection against DOX-induced cardiotoxicity. Lisinopril 61-64 angiotensin I converting enzyme Rattus norvegicus 72-101 35093482-5 2022 Mitigation of radiation-induced pneumonitis with the ACE-inhibitor lisinopril was evaluated in the 13.5 Gy rat PBI model. Lisinopril 67-77 angiotensin I converting enzyme Rattus norvegicus 53-56 35311118-5 2022 One irradiated group was treated with the ACE-inhibitor lisinopril, and a separate group in each strain served as nonirradiated controls. Lisinopril 56-66 angiotensin I converting enzyme Rattus norvegicus 42-45 2559191-0 1989 Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. Lisinopril 113-123 angiotensin I converting enzyme Rattus norvegicus 45-74 2544410-5 1989 Both aldosterone and angiotensin II production could be attenuated by adding the angiotensin converting enzyme inhibitor lisinopril to the culture medium (0.1 mM). Lisinopril 121-131 angiotensin I converting enzyme Rattus norvegicus 81-110 2552823-3 1989 The distribution of ACE was mapped using an iodinated derivative of lisinopril. Lisinopril 68-78 angiotensin I converting enzyme Rattus norvegicus 20-23 2832327-2 1988 Inhibition of angiotensin converting enzyme (ACE) in serum and tissues of rats was studied after administration of lisinopril, an ACE inhibitor. Lisinopril 115-125 angiotensin I converting enzyme Rattus norvegicus 14-43 2838262-1 1988 Angiotensin converting enzyme (ACE) was characterized by radioligand studies utilizing the potent ACE inhibitor 351A, a derivative of lisinopril. Lisinopril 134-144 angiotensin I converting enzyme Rattus norvegicus 0-29 2838262-1 1988 Angiotensin converting enzyme (ACE) was characterized by radioligand studies utilizing the potent ACE inhibitor 351A, a derivative of lisinopril. Lisinopril 134-144 angiotensin I converting enzyme Rattus norvegicus 31-34 2545394-11 1989 Rank order of potency of the ACE inhibitors tested was CI906 = CGS14831 greater than S9780 greater than 351A greater than MK521 greater than SQ27519 Lisinopril 122-127 angiotensin I converting enzyme Rattus norvegicus 29-32 2557876-8 1989 Following oral administration of the drugs to SHR, the degree and duration of ACE inhibition in aorta and lung correlated with the antihypertensive actions, with ramipril, lisinopril, and zofenopril producing effects of the greatest magnitude and duration. Lisinopril 172-182 angiotensin I converting enzyme Rattus norvegicus 78-81 2853724-3 1988 Thereafter the rats were further separated randomly to receive the ACE inhibitor lisinopril (3-8 mg/kg per day) or no drug treatment for 11 weeks. Lisinopril 81-91 angiotensin I converting enzyme Rattus norvegicus 67-70 2846685-0 1988 Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats. Lisinopril 56-66 angiotensin I converting enzyme Rattus norvegicus 15-44 2846685-5 1988 Lisinopril reduced systolic blood pressure and inhibited serum ACE activity in both normal and diabetic rats in a dose-response fashion. Lisinopril 0-10 angiotensin I converting enzyme Rattus norvegicus 63-66 2832327-2 1988 Inhibition of angiotensin converting enzyme (ACE) in serum and tissues of rats was studied after administration of lisinopril, an ACE inhibitor. Lisinopril 115-125 angiotensin I converting enzyme Rattus norvegicus 45-48 2832327-4 1988 Following oral administration of lisinopril (10 mg/kg), serum ACE activity was acutely reduced but recovered gradually over 24 hours. Lisinopril 33-43 angiotensin I converting enzyme Rattus norvegicus 62-65 2832327-5 1988 Four hours after lisinopril administration, ACE activity was markedly inhibited in kidney (11% of control level), adrenal (8%), duodenum (8%), and lung (33%; p less than 0.05). Lisinopril 17-27 angiotensin I converting enzyme Rattus norvegicus 44-47 2832327-7 1988 In brain, ACE activity was markedly reduced 4 hours after lisinopril administration in the circumventricular organs, including the subfornical organ (16-22%) and organum vasculosum of the lamina terminalis (7%; p less than 0.05). Lisinopril 58-68 angiotensin I converting enzyme Rattus norvegicus 10-13 2832327-10 1988 These results establish that lisinopril has differential effects on inhibiting ACE in different tissues and suggest that the prolonged tissue ACE inhibition after a single oral dose of lisinopril may reflect targets involved in the hypotensive action of ACE inhibitors. Lisinopril 29-39 angiotensin I converting enzyme Rattus norvegicus 79-82 2832327-10 1988 These results establish that lisinopril has differential effects on inhibiting ACE in different tissues and suggest that the prolonged tissue ACE inhibition after a single oral dose of lisinopril may reflect targets involved in the hypotensive action of ACE inhibitors. Lisinopril 185-195 angiotensin I converting enzyme Rattus norvegicus 142-145 2832327-10 1988 These results establish that lisinopril has differential effects on inhibiting ACE in different tissues and suggest that the prolonged tissue ACE inhibition after a single oral dose of lisinopril may reflect targets involved in the hypotensive action of ACE inhibitors. Lisinopril 185-195 angiotensin I converting enzyme Rattus norvegicus 142-145 2849698-5 1988 Lung ACE content was quantitated by measuring the single-pass binding of an iodinated ACE inhibitor, 125I-MK 351A, a derivative of lisinopril. Lisinopril 131-141 angiotensin I converting enzyme Rattus norvegicus 5-8 3208727-5 1988 Lung vascular ACE content was quantitated by measuring the single pass binding of an iodinated-converting enzyme inhibitor, 125I-MK351A, a derivative of lisinopril. Lisinopril 153-163 angiotensin I converting enzyme Rattus norvegicus 14-17 2849698-5 1988 Lung ACE content was quantitated by measuring the single-pass binding of an iodinated ACE inhibitor, 125I-MK 351A, a derivative of lisinopril. Lisinopril 131-141 angiotensin I converting enzyme Rattus norvegicus 86-89 33013477-8 2020 Moreover, additional blood pressure lowering of about 22 mmHg could be achieved when BTTQ was administered on top of ACE inhibitor lisinopril, a current standard of care in the treatment of hypertension. Lisinopril 131-141 angiotensin I converting enzyme Rattus norvegicus 117-120 2822313-0 1987 Pharmacokinetics of angiotensin converting enzyme inhibition in tissues following oral lisinopril: studies in the rat using quantitative radioinhibitor binding. Lisinopril 87-97 angiotensin I converting enzyme Rattus norvegicus 20-49 2822313-10 1987 Individual tissues in the rat had differences in time course and degree of ACE inhibition after a single dose of lisinopril. Lisinopril 113-123 angiotensin I converting enzyme Rattus norvegicus 75-78 2822304-0 1987 Blockade of angiotensin converting enzyme in circumventricular organs of the brain after oral lisinopril administration demonstrated by quantitative in vitro autoradiography. Lisinopril 94-104 angiotensin I converting enzyme Rattus norvegicus 12-41 2822304-2 1987 To elucidate the central effect of lisinopril, a new angiotensin converting enzyme (ACE) inhibitor, ACE localization and levels were followed in the brain of Sprague-Dawley rats by quantitative in vitro autoradiography after administration of the drug. Lisinopril 35-45 angiotensin I converting enzyme Rattus norvegicus 53-82 2822304-2 1987 To elucidate the central effect of lisinopril, a new angiotensin converting enzyme (ACE) inhibitor, ACE localization and levels were followed in the brain of Sprague-Dawley rats by quantitative in vitro autoradiography after administration of the drug. Lisinopril 35-45 angiotensin I converting enzyme Rattus norvegicus 84-87 2822304-7 1987 Lisinopril inhibited brain ACE in the subfornical organ and organum vasculosum of the lamina terminalis, circumventricular organs, where the blood brain barrier is deficient. Lisinopril 0-10 angiotensin I converting enzyme Rattus norvegicus 27-30 33986677-5 2021 The goal of the current study is to compare the pharmacokinetics (PK) of a lead angiotensin converting enzyme (ACE) inhibitor, lisinopril, in irradiated vs. nonirradiated rats, as a step toward licensure by the FDA. Lisinopril 127-137 angiotensin I converting enzyme Rattus norvegicus 80-109 33986677-5 2021 The goal of the current study is to compare the pharmacokinetics (PK) of a lead angiotensin converting enzyme (ACE) inhibitor, lisinopril, in irradiated vs. nonirradiated rats, as a step toward licensure by the FDA. Lisinopril 127-137 angiotensin I converting enzyme Rattus norvegicus 111-114 32605800-7 2020 In a parallel study, rats given N-omega-nitro-L-arginine and the angiotensin converting enzyme inhibitor lisinopril at a relatively low dose in their food were divided into two groups; without and with thiosulfate in the drinking water. Lisinopril 105-115 angiotensin I converting enzyme Rattus norvegicus 65-94 32422184-11 2020 However, co-treatment with either Naringenin or Lisinopril mitigated both renal and neuronal oxidative stress, normalized blood pressure and lowered the expressions of kidney injury molecule 1, mineralocorticoid receptor and angiotensin converting enzyme. Lisinopril 48-58 angiotensin I converting enzyme Rattus norvegicus 225-254 28445490-2 2017 It has also been shown that the ACE inhibitor lisinopril, and the natural product curcumin are also beneficial in different models of CKD in rats. Lisinopril 46-56 angiotensin I converting enzyme Rattus norvegicus 32-35 28695320-11 2018 Pretreatment with ACE inhibitor lisinopril (0.5 nmol/100 nL) reduced the pressor response, but did not affect ARS-evoked tachycardia. Lisinopril 32-42 angiotensin I converting enzyme Rattus norvegicus 18-21 31994092-10 2017 RESULTS: All examined ACE-Is: lisinopril, perindopril and ramipril decreased KYNA production in rat kidney in vitro. Lisinopril 30-40 angiotensin I converting enzyme Rattus norvegicus 22-25 28364692-10 2017 RESULTS: All examined ACE-Is: lisinopril, perindopril and ramipril decreased KYNA production in rat kidney in vitro. Lisinopril 30-40 angiotensin I converting enzyme Rattus norvegicus 22-25 26943616-0 2016 Garlic capsule and selenium-vitamins ACE combination therapy modulate key antioxidant proteins and cellular adenosine triphosphate in lisinopril-induced lung damage in rats. Lisinopril 134-144 angiotensin I converting enzyme Rattus norvegicus 37-40 27288733-4 2016 Treatment with either B1 receptor antagonist (BI113823) or an ACE inhibitor (lisinopril) alone or in combination significantly reduced the heart weight-to-body weight and lung weight-to-body weight ratios, and improved postinfarction cardiac function as evidenced by greater cardiac output, the maximum rate of left ventricular pressure rise (+-dP/dtmax), left ventricle ejection fraction, fractional shorting, better wall motion, and attenuation of elevated left ventricular end diastolic pressure (LVEDP). Lisinopril 77-87 angiotensin I converting enzyme Rattus norvegicus 62-65 28416926-2 2017 We aim to investigate the role of COX enzymes in the effects of losartan, an angiotensin II (Ang II) receptor antagonist or lisinopril, an ACE inhibitor, on the contractions of rat thoracic aorta in isolated tissue bath. Lisinopril 124-134 angiotensin I converting enzyme Rattus norvegicus 139-142 27682899-6 2016 In this model, the ACE inhibitor lisinopril (at ~24 mg m d started orally in the drinking water at 7 d after irradiation and continued to >=150 d) mitigated late effects in the lungs and kidneys after 12.5-Gy leg-out PBI. Lisinopril 33-43 angiotensin I converting enzyme Rattus norvegicus 19-22 27976638-3 2016 The present study has been conducted to evaluate the potential effect of an ACE inhibitor, lisinopril, on the morphological and biochemical aspects of fibrotic liver regeneration. Lisinopril 91-101 angiotensin I converting enzyme Rattus norvegicus 76-79 27976638-11 2016 CONCLUSION: ACE inhibitor lisinopril did not produce major histomorphological alterations in regenerating fibrotic liver following partial hepatectomy, however, it may improve its functional capability. Lisinopril 26-36 angiotensin I converting enzyme Rattus norvegicus 12-15 26792980-5 2016 In a docking analysis with testicular ACE (tACE), the most promising inhibitor (4j) was efficiently accommodated in the deep cleft of the protein cavity, making close interatomic contacts with Glu162, His353, and Ala356, comparable with lisinopril. Lisinopril 237-247 angiotensin I converting enzyme Rattus norvegicus 38-41 25757657-8 2015 Further corroboration of LisW-S C-domain specificity is that only lisinopril increased the circulating levels of the N-domain ACE substrate Ac-SDKP. Lisinopril 66-76 angiotensin I converting enzyme Rattus norvegicus 126-129 24464858-2 2015 Candesartan (AT1 antagonist) and lisinopril (ACE inhibitor) has been reported to possess antioxidant and neuroprotective effects. Lisinopril 33-43 angiotensin I converting enzyme Rattus norvegicus 45-48 25837018-1 2015 BACKGROUND: Angiotensin converting enzyme (ACE) inhibitors such as lisinopril, represent the front line pharmacological treatment for heart failure, which is characterised by marked left ventricular (LV) dilatation and hypertrophy. Lisinopril 67-77 angiotensin I converting enzyme Rattus norvegicus 12-41 25837018-1 2015 BACKGROUND: Angiotensin converting enzyme (ACE) inhibitors such as lisinopril, represent the front line pharmacological treatment for heart failure, which is characterised by marked left ventricular (LV) dilatation and hypertrophy. Lisinopril 67-77 angiotensin I converting enzyme Rattus norvegicus 43-46 24450223-5 2013 The ACE inhibitors, particularly hydrophilic lysinopril, to the lesser degree than beta-adrenoblockers, prevented death of animals at the period of the CHF decompensation. Lisinopril 45-55 angiotensin I converting enzyme Rattus norvegicus 4-7 24937322-5 2014 Renovascular hypertensive rats received bilateral PVN infusion with ACE inhibitor lisinopril (LSP, 10mug/h) or vehicle via osmotic minipump for 4weeks. Lisinopril 82-92 angiotensin I converting enzyme Rattus norvegicus 68-71 24561703-4 2014 Lisinopril-tryptophan (LisW-S), an analogue of the ACE inhibitor lisinopril, is highly selective for the C-domain. Lisinopril 65-75 angiotensin I converting enzyme Rattus norvegicus 51-54 22490446-5 2012 Ang I and Ang II forming activities for serum ACE were 102+-4 and 104+-3 fmol/ml/min serum (n=3), respectively, and both products were abolished by the potent ACE inhibitor lisinopril. Lisinopril 173-183 angiotensin I converting enzyme Rattus norvegicus 46-49 22490446-5 2012 Ang I and Ang II forming activities for serum ACE were 102+-4 and 104+-3 fmol/ml/min serum (n=3), respectively, and both products were abolished by the potent ACE inhibitor lisinopril. Lisinopril 173-183 angiotensin I converting enzyme Rattus norvegicus 159-162 22943192-3 2012 In this study, we examined the effects of lisinopril, an ACE inhibitor, on the levels of hippocampal NMDAR subunits; NR2A and NR2B in L-NAME (N(epsilon)-nitro-L-arginine Methyl Ester)-induced hypertensive rats. Lisinopril 42-52 angiotensin I converting enzyme Rattus norvegicus 57-60 22498331-2 2012 BACKGROUND: High-affinity technetium-99m-labeled lisinopril (Tc-Lis) has been shown to specifically localize in tissues that express ACE in vivo, such as the lungs. Lisinopril 49-59 angiotensin I converting enzyme Rattus norvegicus 133-136